Clinical trials during post-COVID pandemic: An interim review
10.12092/j.issn.1009-2501.2020.05.017
- VernacularTitle: 后新冠肺炎疫情下临床试验的发展及思考
- Author:
Zhijun HUANG
1
Author Information
1. Research Center for Clinical Trial, The Third Xiangya Hospital, Central South University
- Publication Type:Journal Article
- Keywords:
Clinical trial;
Corona virus disease 2019;
Pandemic
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2020;25(5):591-594
- CountryChina
- Language:Chinese
-
Abstract:
China has experienced an unprecedented pandemic of corona virus disease 2019 (COVID-19) in 2020. In the background of serious public health events, clinical trials in most Chinese regions have experienced a series of tough periods such as suspension of admission and protocol violation. With resumption of work and production around the country, China has entered the post-COVID pandemic period. This article analyzes how clinical trial institutions resume professional work, and advocates to continue to strengthen the countermeasures and experience during the outbreak, such as the design of subject-centered clinical trial, comprehensively promotion of information technology, construction of professional clinical research centers and clinical research support teams, respecting evidence-based evidence and real-world evidence, optimal ethical committee review modes, and standardization of agency disaster recovery plan. These experiences should be applied to future clinical researches.
